Overview
- A Nature Metabolism paper from a University of Florida team combined electronic health record analysis with brain tissue studies and mouse experiments to examine glucosamine and dementia.
- The health‑record analysis compared about 24,000 people with dementia and 41,000 with mild cognitive impairment and found roughly 8% had documented glucosamine use.
- Among those patients the study reported an about 25% higher likelihood of progressing from mild cognitive impairment to dementia and a similar 25% higher mortality association for people with dementia.
- Laboratory work showed increased N‑glycan abundance (hyperglycosylation) in Alzheimer’s brain tissue, that feeding glucosamine raised glycosylation and worsened memory in Alzheimer’s mouse models, and that blocking key glycosylation enzymes improved cognition in mice.
- Authors stress the human findings are observational and cannot prove causation, and they call for longitudinal follow‑ups of people who stop the supplement, biomarker studies, clinical evaluations where ethical, and testing drugs that target glycosylation pathways because glucosamine is a widely used over‑the‑counter product.